•
Dec 31, 2024
Axsome Q4 2024 Earnings Report
Axsome reported strong revenue growth in Q4 2024, driven by Auvelity sales, while reducing net losses.
Key Takeaways
Axsome Therapeutics posted a 66% YoY increase in revenue, reaching $118.77 million in Q4 2024. Auvelity sales surged 89%, while Sunosi revenue grew 16%. Despite higher R&D and SG&A expenses, the company reduced its net loss compared to Q4 2023. Axsome remains focused on advancing its late-stage pipeline, with upcoming NDA submissions and the anticipated launch of Symbravo.
Revenue increased 66% YoY to $118.77 million.
Auvelity sales grew 89% YoY, reaching $92.61 million.
Net loss reduced to $74.91 million from $98.65 million in Q4 2023.
Cash reserves of $315.35 million are expected to fund operations into profitability.
Axsome
Axsome
Forward Guidance
Axsome expects continued revenue growth driven by Auvelity and Sunosi, while preparing for multiple NDA submissions in 2025.
Positive Outlook
- Auvelity sales momentum expected to continue.
- Symbravo launch planned within four months.
- NDA submissions for AXS-05 and AXS-12 anticipated in 2H 2025.
- Payer coverage improving for key products.
- Cash reserves expected to sustain operations into profitability.
Challenges Ahead
- Net losses remain significant despite improvements.
- R&D expenses expected to stay high due to clinical trials.
- SG&A costs likely to increase with new product launches.
- Competition in CNS therapeutics remains strong.
- Regulatory approval timelines could impact revenue projections.